We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App





First-of-Its-Kind End-to-End Digital Health Platform Automates and Simplifies Diagnostic COVID-19 Testing Experience

By LabMedica International staff writers
Posted on 31 Aug 2021
Print article
Illustration
Illustration
A new end-to-end digital health platform automates and simplifies diagnostic testing experience by transforming connectivity between clinical labs, providers, and patients, thus creating a testing ecosystem.

PreciseMDX (Palo Alto, CA, USA) has launched a cloud-based solution that automates and simplifies the diagnostic testing experience, empowering labs to deliver a transformative journey to providers and patients. PreciseMDX dramatically improves connectivity between clinical labs, providers, and patients during every step of the diagnostic testing process for any type of test.

The first-of-its-kind platform enables labs of any size to quickly and seamlessly set up rapidly scalable, personalized, digital experiences that providers and patients expect in this post-pandemic era where consumer adoption of virtual care has skyrocketed. The unexpected volume of COVID-19 testing has exposed the costs and risks associated with manual data management. PreciseMDX replaces manual data entry with an automated flexible end-to-end solution that works seamlessly with any LIS or LIMS, allowing labs to scale their business and streamline workflow, resulting in significant time and cost savings.

PreciseMDX is designed to eliminate complexity for all users - from scheduling and check-in to coordinating on-site or at-home testing to results notification and reporting. Labs receive step-by-step user onboarding, and easily customizable test orders management software - all from the cloud, allowing for deployment in days, not weeks or months. The PreciseMDX solution supports any type of diagnostic test, including: women's & men's health (fertility, prenatal, cancer, testosterone), sexual health (STIs, HPV, UTI), wellness/nutrition (nutrition DNA kit, food allergy/intolerances), COVID-19 testing, respiratory, nail fungal wound panels, and vaccines.

"The scramble to ramp up testing during COVID-19, exposed a need in the healthcare industry for an automated diagnostic testing experience so that labs can scale rapidly, patients can have control over the process and receive results quickly, and providers can treat patients quicker with a faster, more connected system," said Mark Dorner, co-Founder & Chief Executive Officer of PreciseMDX. "We saw this need and created a technology to completely transform the diagnostic testing experience to one that is automated, simple, and user friendly. Today, this is what patients expect."

Related Links:
PreciseMDX

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.